The size of the Latin America NGS Market is anticipated to grow with a CAGR of 19.06% and reach USD 0.7 Billion by 2024.
Next-generation sequencing (NGS) is the term used to refer to a number of different modern sequencing techniques, often known as high-throughput sequencing. These techniques allow sequencing of DNA and RNA much faster and cheaper than commonly used Sanger sequencing, revolutionizing genomics and molecular biology research as such.
In healthcare markets, Latin America is a priority. The country has experienced its highest economic growth in the last four decades. Economics took nearly a quarter of the region's total population to middle-class status, with about 70% residing in Brazil, Mexico, and Argentina. Economic development has transformed into investment in the healthcare systems of this country, which in terms of expenditure on high-end biotechnology resources for clinical research and diagnostics has increased emphasis.
Genomics studies Latin America's product cycle with next-generation sequencing technology is in its exponential stage, and market growth is higher than global investment in science and technology relative to S&T spending as a relative percentage of GDP.
Growth in personalized medicine, development of pre-sequencing and NGS bioinformatics solutions, and cloud computing enhanced NGS application, population growth, and increased incidences of contagious diseases are few factors driving the market growth.
One of the challenges facing Latin America's next-generation sequencing market is the processing and management of data generated by sequencing and its analysis, high quality of government grants and funding and reduced capital expenditure from academic institutions.
However, projected declines in genome sequencing prices due to the development by key players of quick, high-capacity whole genome sequencers are expected to have a positive impact on market penetration levels over the next few years.
This research report segmented and sub-segmented into the following categories:
In Latin America, owing to the rise in the investments in diagnostic research and development, there is ample scope for the market to grow along the period. The countries are focused on providing personalized treatment and therapies to the people with the use of technologies like NGS, data analytics.
Top companies in the market
Promising companies in the Latin America Next Generation Sequencing (NGS) Market Illumina Incorporated, Thermo Fischer Scientific, Life Sciences (Roche), Pacific Biosciences, Life Technologies Corp. (Thermo Fischer Scientific), Macrogen Inc., Partek Inc., Genomatix Software GmbH, Perkin Elmer inc., GATC Biotech Ag, Agilent Technologies Inc., Biomatters Ltd., CLC Bio (Qiagen), BGI (Beijing Genomics Institute), Oxford Nanopore Technologies Ltd., Pacific Biosciences, DNASTAR Inc., Knome Inc., and Qiagen N.V.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Analysis Design
2.3 Research Phases
2.3.1 Secondary Research
2.3.2 Primary Research
2.3.3 Econometric Modelling
2.3.4 Expert Validation
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Product
5.1.1 Software
5.1.2 Services
5.2 By Technology
5.2.1 Whole Targeted Re-Sequencing
5.2.2 Genome Sequencing
5.2.3 De Novo Sequencing
5.2.4 Exome Sequencing
5.2.5 RNA-Seq
5.2.6 ChIP-Seq
5.2.7 Methyl-Seq
5.3 By Application
5.3.1 Diagnostics
5.3.2 Drug Discovery
5.3.3 Biomarker Discovery
5.3.4 Personalized Medicine
5.3.5 Agriculture and Animals Research
6. Geographical Analysis
6.1 Introduction
6.2 Brazil
6.3 Argentina
6.4 Mexico
6.5 Rest of Latin America
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Macrogen Inc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Thermo Fischer Scientific
8.3 Life Sciences (Roche)
8.4 Pacific Biosciences
8.5 Life Technologies Corp.
8.6 Partek Inc.
8.7 Genomatix Software GmbH
8.8 Perkin Elmer inc.
8.9 GATC Biotech Ag
8.10 Agilent Technologies Inc.
8.11 Biomatters Ltd.
8.12 CLC Bio (Qiagen)
8.13 Pacific Biosciences
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
